Skip to content

The synergistic effect of methylphenidate on the treatment of post-traumatic stress disorder: A pilot study

The synergistic effect of methylphenidate on the treatment of post-traumatic stress disorder

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500097795
Enrollment
Unknown
Registered
2025-02-25
Start date
2025-03-03
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-traumatic stress disorder

Interventions

methylphenidate combined trauma-focused therapy group (phase 1):Traumatic-focused therapy is conducted once a week for approximately 60 minutes each time. Before each psychological treatment, take one
Traumatic-focused therapy group (phase 2):Traumatic-focused therapy is conducted once a week for approximately 60 minutes each time. Before each psychological treatment.
methylphenidate combined trauma-focused therapy group (phase 2):Traumatic-focused therapy is conducted once a week for approximately 60 minutes each time. Before each psychological treatment, take one
placebo combined trauma-focused therapy group (phase 2):Traumatic-focused therapy is conducted once a week for approximately 60 minutes each time. Before each psychological treatment, take one placebo

Sponsors

Peking University Sixth Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Adults aged 18-60 who meet all the criteria for PTSD in the CAPS-5 assessment of DSM-5. (2) CAPS-5 overall severity score 20-50. (3) The duration of symptoms is >= 6 months. (4) Have never taken psychotropic drugs, or have maintained a stable dosage of psychotropic drugs for more than 4 weeks.

Exclusion criteria

Exclusion criteria: (1) Have suffered from or currently suffer from primary psychiatric disorders, bipolar disorder, dissociative identity disorder, eating disorders with active clearance function, severe depressive disorders with psychiatric characteristics, personality disorders, severe alcohol or marijuana use disorders, and any substance use disorders within the 12 months prior to enrollment. (2) ADHD patients. (3) Organic mental disorders or neurological disorders. (4) Existence of suicidal tendencies (Colombian Suicide Scale score >= 4). (5) BMI24kg/m ². (6) Pregnant or breastfeeding. (7) Currently undergoing electroconvulsive therapy or other physical therapy. (8) Currently participating in other research.

Design outcomes

Primary

MeasureTime frame
clinician-administered PTSD scale score;

Secondary

MeasureTime frame
Hamilton depression scale score;Hamilton anxiety scale score;clinical global impression score;

Countries

China

Contacts

Public ContactYing Qian

Peking University Sixth Hospital

qiy427@163.com+86 138 1168 7906

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026